Literature DB >> 14659797

Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.

Cédric Blanpain1, Emmanuel Le Poul, Jasmine Parma, Christiane Knoop, Michel Detheux, Marc Parmentier, Gilbert Vassart, Marc J Abramowicz.   

Abstract

OBJECTIVE: Appetite-suppressant drug fenfluramine is implicated in primary pulmonary hypertension (PPH) but the molecular pathways that mediate this effect are unknown. A mouse model incriminates the serotonin 5-HT(2B) receptor but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via nitric oxide production.
METHODS: We analyzed the human 5-HT(2B) gene in 10 patients with appetite-suppressant drug-associated PPH.
RESULTS: A mutation causing premature truncation of the protein product was found in one patient. The mutation was not found in 80 control subjects and no 5-HT(2B) mutation was found in 18 PPH patients not associated with appetite-suppressants. Functional analysis of the transfected receptor expressed either transiently in COS cells or stably in CHO cells demonstrated that the mutated receptor fails to activate the second messenger inositol-phosphates cascade and subsequent intracellular calcium release, in spite of normal expression at the cell membrane. The mutated receptor had no constitutive activity, and produced no dominant negative effect on the wild-type receptor.
CONCLUSION: Loss of serotonin 5-HT(2B) receptor function may predispose to fenfluramine-associated PPH in man.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659797     DOI: 10.1016/j.cardiores.2003.09.015

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

Review 1.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  GPCRs in pulmonary arterial hypertension: tipping the balance.

Authors:  Jean Iyinikkel; Fiona Murray
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

Review 3.  Pulmonary hypertension: therapeutic targets within the serotonin system.

Authors:  Y Dempsie; M R MacLean
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 4.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  A population-specific HTR2B stop codon predisposes to severe impulsivity.

Authors:  Laura Bevilacqua; Stéphane Doly; Jaakko Kaprio; Qiaoping Yuan; Roope Tikkanen; Tiina Paunio; Zhifeng Zhou; Juho Wedenoja; Luc Maroteaux; Silvina Diaz; Arnaud Belmer; Colin A Hodgkinson; Liliana Dell'osso; Jaana Suvisaari; Emil Coccaro; Richard J Rose; Leena Peltonen; Matti Virkkunen; David Goldman
Journal:  Nature       Date:  2010-12-23       Impact factor: 49.962

6.  Effect of serotonin reuptake inhibitors on pulmonary hemodynamics in humans.

Authors:  Hilde Pleym; Guri Greiff; Tom Mjorndal; Roar Stenseth; Alexander Wahba; Olav Spigset
Journal:  J Clin Med Res       Date:  2011-09-26

7.  The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series).

Authors:  Margaret Mandy R MacLean
Journal:  Pulm Circ       Date:  2018 Apr-Jun       Impact factor: 3.017

Review 8.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.